{"filing":{"accession_number":"0001776985-26-000072","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"form6-krosettabreastx0122o.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000072/form6-krosettabreastx0122o.htm"},"events":[{"id":37053,"run_id":34153,"accession_number":"0001776985-26-000072","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a clinical trial collaboration and supply agreement between BioNTech and Gilead Sciences to evaluate pumitamig in combination with sacituzumab govitecan in the ROSETTA Breast-01 Phase 3 trial for triple-negative breast cancer. The announcement describes an adaptation of an ongoing trial to reflect evolving standard of care and represents a material operational/strategic development in BioNTech's oncology pipeline, but does not constitute a discrete M\u0026A transaction, earnings disclosure, executive change, or other specifically-named event type. The collaboration is material to investors as it reflects progress in a key late-stage development program and partnership strategy.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-10-22","form":"6-K","submitted_at":null,"items":[{"id":41639,"accession_number":"0001776985-26-000072","item_number":"EX-99.1","item_title":"a991261022_bntxrosettabrea.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a clinical trial collaboration and supply agreement between BioNTech and Gilead Sciences to evaluate pumitamig in combination with sacituzumab govitecan in the ROSETTA Breast-01 Phase 3 trial for triple-negative breast cancer. The announcement describes an adaptation of an ongoing trial to reflect evolving standard of care and represents a material operational/strategic development in BioNTech's oncology pipeline, but does not constitute a discrete M\u0026A transaction, earnings disclosure, executive change, or other specifically-named event type. The collaboration is material to investors as it reflects progress in a key late-stage development program and partnership strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:50:38.269337+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41639,"accession_number":"0001776985-26-000072","item_number":"EX-99.1","item_title":"a991261022_bntxrosettabrea.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a clinical trial collaboration and supply agreement between BioNTech and Gilead Sciences to evaluate pumitamig in combination with sacituzumab govitecan in the ROSETTA Breast-01 Phase 3 trial for triple-negative breast cancer. The announcement describes an adaptation of an ongoing trial to reflect evolving standard of care and represents a material operational/strategic development in BioNTech's oncology pipeline, but does not constitute a discrete M\u0026A transaction, earnings disclosure, executive change, or other specifically-named event type. The collaboration is material to investors as it reflects progress in a key late-stage development program and partnership strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:50:38.269337+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-10-22"}]}